Sinopharm Group Co. Ltd. — Earnings Release 2025

Aug 29, 2025

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

国药集团

SINOPHARM

國藥控股股份有限公司

SINOPHARM GROUP CO. LTD.*

(A joint stock limited company incorporated in the People's Republic of China with limited liability and carrying on business in Hong Kong as 國控股份有限公司)

(Stock Code: 01099)

ANNOUNCEMENT PRINCIPAL UNAUDITED ACCOUNTING DATA AND FINANCIAL INDICATORS OF SINOPHARM ACCORD FOR THE SIX MONTHS ENDED 30 JUNE 2025

This announcement is made pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and Part XIVA of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong).

Reference is made to the overseas regulatory announcement of Sinopharm Group Co. Ltd. (the "Company") dated 29 August 2025 (the "Announcement") in relation to the 2025 interim report of China National Accord Medicines Corporation Ltd. ("Sinopharm Accord"), a subsidiary of the Company and whose A shares and B shares are listed on the Shenzhen Stock Exchange (stock code for A shares: 000028; stock code for B shares: 200028).

The board of directors of the Company would like to draw the attention of its shareholders and the public investors to the following principal unaudited accounting data and financial indicators of Sinopharm Accord for the six months ended 30 June 2025 as set out in the Announcement.

• The Company is registered as a non-Hong Kong company under the Hong Kong Companies Ordinance under its Chinese name and the English name "Sinopharm Group Co. Ltd."

---

PRINCIPAL UNAUDITED ACCOUNTING DATA AND FINANCIAL INDICATORS OF SINOPHARM ACCORD

Unit: Yuan
Currency: RMB

	The Reporting Period	Same period of last year	Increase/Decrease (%)
Revenue	36,796,598,397.42	37,785,980,620.95	-2.62
Net profit attributable to shareholders of the listed company	665,907,312.44	743,487,174.84	-10.43
Net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses	642,861,567.03	711,378,482.12	-9.63
Net cash flow arising from operating activities	15,066,690.28	929,377,508.78	-98.38
Basic earnings per share (Yuan/Share)	1.20	1.34	-10.45
Diluted earnings per share (Yuan/Share)	1.20	1.34	-10.45
Weighted average return on net assets	3.70%	4.19%	Decreased by 0.49 percentage point
	At the end of the Reporting Period	At the beginning of the Reporting Period	Increase/Decrease (%)
Total assets	50,426,135,786.96	47,555,860,415.22	6.04
Net assets attributable to shareholders of listed company	18,136,171,801.70	17,669,528,375.65	2.64

By order of the Board
Sinopharm Group Co. Ltd.
Zhao Bingxiang
Chairman

Shanghai, the PRC
29 August 2025

As at the date of this announcement, the executive Directors are Mr. Lian Wanyong and Mr. Sun Jinglin; the non-executive Directors are Mr. Zhao Bingxiang, Mr. Chen Qiyu, Mr. Zu Jing, Mr. Xing Yonggang, Mr. Chen Yuqing, Mr. Wen Deyong and Ms. Feng Rongli; and the independent non-executive Directors are Mr. Li Peiyu, Mr. Wu Tak Lung, Mr. Yu Weifeng, Mr. Shi Shenghao and Mr. Chen Weiru.

2